ArticleRespiration; international review of thoracic diseases2025
Evaluation of Treatment Adjustments and the Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Complications in Patients Undergoing Diagnostic Bronchoscopy.
Article in Respiration; international review of thoracic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs) increase the risk of bleeding during invasive procedures such as bronchoscopy. To mitigate this risk, NOACs are typically held before bronchoscopy. Current guidelines for discontinuing NOACs are based on drug half-lives and recommendations from similar invasive procedures. This study aimed to evaluate the safety of our local protocols for pausing NOAC therapy prior to bronchoscopy.
methodsWe performed a retrospective review of patients treated with NOACs who underwent bronchoscopy with invasive sampling in 2023. We adhered to local guidelines for NOAC discontinuation before procedures with a high bleeding risk. We documented bleeding incidents during bronchoscopy and any potential thromboembolic events, comparing these outcomes with a control group of 75 patients on acetylsalicylic acid (ASA) and 77 patients not on any anticoagulant (ACT) or antiplatelet (APT) therapy.
resultsOut of 1,300 patients who had bronchoscopy in 2023, 100 were on NOACs (48 on rivaroxaban, 36 on apixaban, 12 on dabigatran, and 4 on edoxaban). We further analyzed 75 patients who had invasive sampling: transbronchial biopsy in 49; bronchial biopsy in 12; EBUS-guided transbronchial needle aspiration in 42; and conventional TBNA in 18. Mild to moderate bleeding occurred in 9 of these 75 patients (12%) receiving NOACs, compared to 11 of 75 patients (14.7%) on ASA and 7 of 77 patients (9.1%) without ACT or APT therapy. Bleeding was observed in patients with either lung cancer (n = 16) or interstitial lung disease (n = 10), with one exception. There was no significant association between bleeding and factors such as age, platelet count, or INR levels. No severe bleeding or thromboembolic events were reported in any of the groups.
conclusionFollowing local recommendations for NOAC discontinuation before bronchoscopy is effective in minimizing complications and ensuring patient safety during invasive procedures. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.